SEC Form 4 · accession 0001209191-15-013504

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Feb 11, 2015

Accepted (ET)

Feb 13, 2015 · 4:14 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Feb 11, 2015	M	1,300	$17.16	A	340,195	D
Common Stock	Feb 11, 2015	M	4,400	$35.64	A	344,595	D
Common Stock^F2,F3	Feb 11, 2015	S	2,400	$108.20	D	342,195	D
Common Stock^F3,F4	Feb 11, 2015	S	3,100	$108.87	D	339,095	D
Common Stock^F3,F5	Feb 11, 2015	S	200	$109.94	D	338,895	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock^F6	holding	—	—		—	172,589	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F7	$17.16	Feb 11, 2015	M	1,300	D	—	Jul 19, 2015	Common Stock	1,300	29,100	D
Stock Option (right to buy)^F7	$35.64	Feb 11, 2015	M	4,400	D	—	Feb 1, 2016	Common Stock	4,400	520,800	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Open market sales reported on this line occurred at a weighted average price of $108.20 (range $107.59 to $108.58).
F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4Open market sales reported on this line occurred at a weighted average price of $108.87 (range $108.60 to $109.52).
F5Open market sales reported on this line occurred at a weighted average price of $109.94 (range $109.86 to $110.02).
F6Common stock held in grantor retained annuity trusts.
F7Fully vested.